N-[4-(4-Amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-methylesulfonamide
| Title | Journal |
|---|---|
| Synthesis and evaluation of 8-oxoadenine derivatives as potent Toll-like receptor 7 agonists with high water solubility. | Bioorganic & medicinal chemistry letters 20130201 |
| Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model. | Journal of clinical immunology 20121001 |
| Prolonged subcutaneous administration of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced hematologic malignancies. | American journal of hematology 20121001 |
| Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers. | Cancer immunology, immunotherapy : CII 20101201 |
| TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN. | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 20080401 |
| An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. | Clinical cancer research : an official journal of the American Association for Cancer Research 20080201 |
| Comparison of human B cell activation by TLR7 and TLR9 agonists. | BMC immunology 20080101 |
| First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20071201 |